Bios I Pharma ApS: Financial statements 2025
CVR: 32672620
Source: annual report 2025, Danish Business Authority
01/10/2024 – 30/09/2025
Bios I Pharma ApS (CVR 32672620) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -68,061 and a net result of DKK 206,285 compared with DKK 1,732,448 the year before. Equity in the 2025 report amounted to DKK 445,202. The solvency ratio was 11.6%.
- Gross Profit
- DKK -68,061
- Profit/Loss
- DKK 206,285
- Equity
- DKK 445,202
- Total Assets
- DKK 3,834,244
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -68K | 206K | 445K | 0 |
| 2024 | - | 2M | 1.7M | 239K | 0 |
| 2023 | - | -1K | 352K | -3M | 0 |
| 2022 | - | 48K | 10K | -3.3M | - |
| 2021 | - | 775 | -68K | -3.4M | - |
Official annual report
How creditworthy is Bios I Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Bios I Pharma ApS has published its annual report for 2024. Gross profit came to DKK 2,012,494, and the net result was DKK 1,732,448.
As of May 14, 2025, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Bios I Pharma ApS.
As of May 14, 2025, Henrik Beier Jessen is registered as director of Bios I Pharma ApS.
As of May 5, 2025, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of Bios I Pharma ApS.
As of May 5, 2025, Henrik Beier Jessen has stepped down as director of Bios I Pharma ApS.
About Bios I Pharma ApS
Bios I Pharma ApS is a Danish company of the type Anpartsselskab based in Aarhus N, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named AC 01 ApS. The management consists of Henrik Beier Jessen. The company is owned by Beier Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -68,061 and a net result of DKK 206,285 compared with DKK 1,732,448 the year before. Equity in the 2025 report amounted to DKK 445,202.